Vasculitis & polymyalgia rheumatica
Management of antineutrophil cytoplasmic antibody vasculitis-associated orbital inflammatory disease: A systematic literature review
Authors' conclusion
Our results suggest high remission rates of OID with RTX but highlight the need for high-quality prospective studies examining treatments for AAV-OID.
Study context
- Population
- Adults treated for ANCA-associated vasculitides (AAV)-associated orbital inflammatory disease (OID); most refractory/relapsing cases
- Participants
- 277 adults18 studies
- Outcome
- Clinical response, defined as any improvement in signs or symptoms, up to and including remission
Methodological detailsrandom effects model, Newcastle-Ottawa Scale appraisal, no language or date restrictions, 14 retrospective cohorts, 4 case series; 17/18 had Newcastle-Ottawa Scale (NOS) scores ≥5, Interventions: Rituximab (RTX) in 13 studies, cyclophosphamide 10, RTX + another immunosuppressant (IS) 7, conventional IS 11, surgical therapies 7
- Random effects model
- Newcastle-Ottawa Scale appraisal
- No language or date restrictions
- 14 retrospective cohorts, 4 case series; 17/18 had NOS scores ≥5
- Interventions: RTX in 13 studies, cyclophosphamide 10, RTX + another IS 7, conventional IS 11, surgical therapies 7
Pooled result
As reported in the abstract
Clinical response
RTX monotherapy
95%
95% CI 89–100%
Further pooled results
| Outcome | Values |
|---|---|
| Remission · 6 months | RTX monotherapy 84% (95% CI 72–95%) |
- Remission: p < 0.001
Original publication
Management of antineutrophil cytoplasmic antibody vasculitis-associated orbital inflammatory disease: A systematic literature review. Semin Arthritis Rheum. Published 23 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →